Tricyclic derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP)
    2.
    发明授权
    Tricyclic derivatives as inhibitors of poly(ADP-ribose) polymerase (PARP) 失效
    作为聚(ADP-核糖)聚合酶(PARP)抑制剂的三环衍生物

    公开(公告)号:US08362030B2

    公开(公告)日:2013-01-29

    申请号:US12922270

    申请日:2009-03-13

    IPC分类号: A61K31/437 C07D471/12

    CPC分类号: C07D471/06 C07D471/16

    摘要: The present invention relates to compounds of formula (I) and pharmaceutically acceptable salts or tautomers thereof which are inhibitors of poly(ADP-ribose)polymerase (PARP) and thus useful for the treatment of cancer, inflammatory diseases, reperfusion injuries, ischaemic conditions, stroke, renal failure, cardiovascular diseases, vascular diseases other than cardiovascular diseases, diabetes mellitus, neurodegenerative diseases, retroviral infections, retinal damage, skin senescence and UV-induced skin damage, and as chemo- or radiosensitizers for cancer treatment.

    摘要翻译: 本发明涉及作为聚(ADP-核糖)聚合酶(PARP)的抑制剂的式(I)化合物及其药学上可接受的盐或互变异构体,因此可用于治疗癌症,炎性疾病,再灌注损伤,缺血状况, 中风,肾衰竭,心血管疾病,心血管疾病以外的血管疾病,糖尿病,神经变性疾病,逆转录病毒感染,视网膜损伤,皮肤衰老和紫外线诱发的皮肤损伤,以及用于癌症治疗的化学或放射增敏剂。